# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.83) per share which beat the analyst consensus estimate o...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel onco...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the ...
Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades.
Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(3.110) per share which missed the analyst consensus estimat...
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...